The entire debate about COVID-19 and Leronlimab...has many
The entire debate about COVID-19 and Leronlimab...has many layers attached to it...The Naders statements about Leronlimabs positive effects on COVID-19 will of course have an affect on how his trial will unfold...and whether he was caught in a lie or not.
On the larger canvas lies the FDA statement about Leronlimabs Nil affect on Covid...something they may end up Walking back...Once its proven to be otherwise...PASC/LH clinical/trials will be very telling.
We are no longer the "Roque Nation" of Biotechs...and our medical team is prosecuting our case for both redemption and future promise to a World of patients.
Once announced...share price will take of itself...OR,...We will be acquired...partnered up...or licensing out indications.
We have a disruptive Molecule...
We have the Team in place to help map out the future moves...and financial landscape.
We have a universe of need to satisfy.
15
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Diplomacy Takes Center Stage So here we are again, riding the rollercoaster of geopolitics that's jerking the oil market around like a marionette. With the U.S. and Iran allegedly chatting—mind you, with a ton of smoke and mirrors through Qatar and Islamabad—every trader's watching, hoping for a ceasefire that might either stabilize or further jolt energy prices. Oil...
Continue Reading
A Steady March Forward for Yum China Yum China's third-quarter results reveal a company moving like a well-oiled machine, even in a turbulent market. A revenue uptick of 8% is no small feat, especially when operating under the weight of a 3% rise in system sales that neatly sidesteps the usual foreign exchange hiccups. This ain't just about keeping the lights on; it's...
Continue Reading
OSL's New Move: Instant Redemption on the Table Alright, let's chew over OSL's latest gambit—you know, those folks (HKEX: 863) who are knee-deep in the digital currency swamp. They've launched this "Instant Redemption" feature for these fancy real-world asset products, and USDGO Plus SP is right there at the forefront. Getting the Fine Print Straight Now, not just...
Continue Reading
Rethinking How Research Data Drives Discovery When researchers generate truckloads of data, finding patterns that lead to breakthroughs often becomes a game of hide and seek. It's like having a jumbo puzzle with pieces scattered all over the place. Enter the NIH Common Fund Data Ecosystem—a game changer attempting to glue together these pieces across the research...
Continue Reading
Marathon's Profit Skyrockets Marathon Petroleum Corp. (NYSE: MPC) just pulled off a Houdini act in the third quarter of 2026, as they reported a staggering net income of $7.4 billion. Compare that to last year's third quarter profits of $1.4 billion, and it's like comparing a sumo wrestler with a featherweight fighter. This transformation isn't just a fluke, it's a result...
Continue Reading
Leadership Shifts in Gallagher's Upper Echelons What a shake-up at Arthur J. Gallagher & Co.! The power torch is officially passing over in its Benefits & HR Consulting Division. Come January 1, 2027, Tom Doyle is strapping in as the new CEO, taking over from William F. "Bill" Ziebell. Now, don't get too teary-eyed—Ziebell's not vanishing into thin air. Instead, he's...
Continue Reading
New Leadership at PASCO scientific Here's the scoop: PASCO scientific is shaking things up at the top by welcoming David Lopez into the CEO chair as of October 5, 2026. Lopez comes packing over two decades of experience in education and organizational leadership. He's stepping into a legacy that's all about making science hands-on and exciting for students—not just in...
Continue Reading
Graphic Packaging's Financial Figures: A Rough Ride Looking at the latest numbers from Graphic Packaging (NYSE: GPK), it's clear that the packaging landscape isn’t all wrapped up in a neat bow. Sure, the top line showed a slight uptick year-on-year with net sales nudging up $2 million to $2,192 million. Volumes were up too—by 1%—but that’s barely a blip when you...
Continue Reading
Clinical Stage Wonders and Bold Claims Here's the lowdown on the latest tale from Verismo Therapeutics, a name that's trying real hard to distinguish itself in the CAR T therapy arena. Grab a coffee, pal, and let's wade through what's cooking at their camp with the SynKIR™-110. Breaking Down the Science Jargon For you folks not knee-deep in immunotherapy, let me spell...
Continue Reading
CPQ Tech: Unpacking the 2026 Manufacturing Landscape In the cutthroat world of manufacturing, it's adapt or die. Right now, happens it's the fixers in Configure, Price, Quote (CPQ) technology, stepping in to save the day. Nucleus Research just dropped their 2026 Manufacturing CPQ Technology Value Matrix, shining a bright spotlight on who’s leading the pack and why it...
Continue Reading
Top 5 Most Recently Viewed Articles
Introducing The Sylvan Lodge The Sylvan Lodge, nestled within the enchanting Snake River Sporting Club, provides an upscale retreat for those seeking an intimate escape in the stunning wilderness of Wyoming. This luxury lodge boasts serene views, a comprehensive spa, and wellness center, along with various dining experiences that elevate the guest experience to new...
Continue Reading
Understanding the Evolv Technologies Holdings Class Action Recent developments have raised significant concerns among shareholders of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV). A class action lawsuit is currently in progress, prompting investors to scrutinize the implications of false statements made by the company. The allegations revolve around misleading...
Continue Reading
Celebrating Excellence in Dermatologic Surgery Advocacy The American Society for Dermatologic Surgery Association (ASDSA), a leading organization advocating for dermatologic surgeons and their patients, has proudly announced its annual award recipients. This announcement highlights the essential contributions made by individuals who play pivotal roles in promoting patient...
Continue Reading
Scholastic Appoints Chris Lick to Leadership Role Scholastic (NASDAQ: SCHL) has recently announced a significant leadership change within its ranks, as Chris Lick steps into the role of Executive Vice President, General Counsel, and Corporate Secretary. This strategic appointment marks a new chapter for Scholastic, one of the leading organizations in children's publishing...
Continue Reading
Pandora Unveils New Share Buyback Programme On February 7, 2024, Pandora revealed a detailed share buyback programme that underscores its dedication to enhancing shareholder value. This initiative complies with Regulation (EU) No 596/2014, which sets the standards for market abuse regulations. Aims of the Share Buyback Programme The main objective of this programme is to...
Continue Reading